MPN | Tumor

Trial to Investigate Experimental Drug’s Effect on Improving Survival in Refractory Myelofibrosis

May 11th 2021, 9:00pm


The Geron Corporation announced that the first patient has been dosed with GRN163L — an experimental agent — in a phase 3 clinical trial to assess the drug’s overall survival benefit compared to best available therapy in patients with refractory myelofibrosis.

Jakafi-Novel Therapy Combo Improves Symptom Burden in Patients with Myelofibrosis

May 11th 2021, 1:00pm


Treatment with daily Jakafi and parsaclisib improved spleen volume reduction and symptom burden in patients with myelofibrosis who had previously failed to achieve significant response to single-agent Jakafi.

Jakafi Reintroduced to Patients with Myelofibrosis After Discontinuation May Extend Survival

April 14th 2021, 1:00pm


Reintroducing treatment with Jakafi in patients with myelofibrosis after previous discontinuation extended overall survival compared to those patients who stopped permanently, although there was a substantial rate of permanent treatment discontinuation with this therapy.

Givinostat Demonstrates Long-Term Clinical Benefit in Polycythemia Vera

April 2nd 2021, 6:00pm


At four-year follow up, treatment with givinostat, a histone-deacetylase inhibitor, continued to be safe and effective with no serious or life-threatening side effects.

Risk of Atrial Fibrillation ‘Substantial’ in Patients with Certain Blood Cancers After Undergoing Allogeneic Hematopoietic Cell Transplantation

March 17th 2021, 9:00pm


Of note, estimates show that there are more than 25,000 patients undergoing allogeneic hematopoietic cell transplantations throughout the United States and beyond. Recent study results show that these patients may be at a higher risk for de novo atrial fibrillation.

EDUCATED PATIENT Myeloproliferative Neoplasms (MPNs) Webinar: December 17, 2020

December 18th 2020, 12:00am


Watch our Myeloproliferative Neoplasms Webinar where an expert panel discussed topics highly relevant to patients, caregivers and advocates right now.

How Higher Doses of Imetelstat May Benefit Patients with Relapsed/Refractory Myelofibrosis

December 6th 2020, 6:23pm


In an interview with CURE®, lead study investigator Dr. John Mascarenhas discusses what the results of the phase 2 IMbark study could mean for the future of patients with myelofibrosis.

High-Dose Imetelstat Could Offer Patients with High-Risk Myelofibrosis Improved Overall Survival

December 5th 2020, 8:00pm


An analysis of the phase 2 study IMbark shows how imetelstat can offer patients with high-risk myelofibrosis multiple clinical benefits, setting the stage for an expanded phase 3 trial.

CURE®’s 8th Annual MPN Heroes Program Honors ‘Team of Warriors’ Who Have Overcome Challenges in Myeloproliferative Neoplasms

December 5th 2020, 3:00pm


Five patient advocates, two oncologists and one caregiver were honored during CURE®’s eighth annual MPN Heroes Program.

MPN Heroes® Recognition Program 2020

December 5th 2020, 12:00am


Watch the entire MPN Heroes program here!